109 related articles for article (PubMed ID: 9796553)
1. Economic impact of resistance in the community.
Eandi M; Zara GP
Int J Clin Pract Suppl; 1998 Jun; 95():27-38. PubMed ID: 9796553
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community].
Bertrán MJ; Trilla A; Codina C; Carné X; Ribas J; Asenjo MA
Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168
[TBL] [Abstract][Full Text] [Related]
3. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines.
Simoens S
Curr Med Res Opin; 2009 Oct; 25(10):2447-57. PubMed ID: 19678752
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic burden of antimicrobial resistance.
Maragakis LL; Perencevich EN; Cosgrove SE
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):751-63. PubMed ID: 18847410
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance.
Doern GV
Expert Rev Anti Infect Ther; 2006 Oct; 4(5):821-35. PubMed ID: 17140358
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance.
Martin M; Quilici S; File T; Garau J; Kureishi A; Kubin M
J Antimicrob Chemother; 2007 May; 59(5):977-89. PubMed ID: 17395688
[TBL] [Abstract][Full Text] [Related]
7. Cost of Gram-negative resistance.
Evans HL; Lefrak SN; Lyman J; Smith RL; Chong TW; McElearney ST; Schulman AR; Hughes MG; Raymond DP; Pruett TL; Sawyer RG
Crit Care Med; 2007 Jan; 35(1):89-95. PubMed ID: 17110877
[TBL] [Abstract][Full Text] [Related]
8. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter?
Nathwani D
J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii37-44. PubMed ID: 12730141
[TBL] [Abstract][Full Text] [Related]
9. [The other side of the coin: socioeconomic analysis of antibiotic resistance].
García-Altés A; Jovell AJ; Aymerich M
Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():27-31. PubMed ID: 10605187
[TBL] [Abstract][Full Text] [Related]
10. Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Rapp RP
Postgrad Med; 2002 Sep; 112(3 Suppl):12-7. PubMed ID: 19667590
[TBL] [Abstract][Full Text] [Related]
11. Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia.
Sabes-Figuera R; Segú JL; Puig-Junoy J; Torres A
Eur J Health Econ; 2008 Feb; 9(1):23-32. PubMed ID: 17221181
[TBL] [Abstract][Full Text] [Related]
12. Streptococcus pneumoniae: does antimicrobial resistance matter?
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
[TBL] [Abstract][Full Text] [Related]
13. [beta-lactam-antibiotics in the treatment of community-acquired respiratory tract infections with penicillin-resistant pneumococci].
Brauers J; Ewig S; Kresken M
Pneumologie; 2002 Oct; 56(10):605-9. PubMed ID: 12375222
[TBL] [Abstract][Full Text] [Related]
14. The impact of antimicrobial resistance on health and economic outcomes.
Cosgrove SE; Carmeli Y
Clin Infect Dis; 2003 Jun; 36(11):1433-7. PubMed ID: 12766839
[TBL] [Abstract][Full Text] [Related]
15. Appropriate antibiotic therapy for community-acquired respiratory tract infections.
Gerbino PP; Brixner D; Sbarbaro J; Nicolau D
Manag Care Interface; 2005 Dec; 18(12):41-8. PubMed ID: 16405224
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial drug use and resistance among respiratory pathogens in the community.
Low DE
Clin Infect Dis; 2001 Sep; 33 Suppl 3():S206-13. PubMed ID: 11524720
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic resistance in community-acquired respiratory tract infections: current issues.
Spach DH; Black D
Ann Allergy Asthma Immunol; 1998 Oct; 81(4):293-302; quiz 302-3. PubMed ID: 9809491
[TBL] [Abstract][Full Text] [Related]
18. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
[TBL] [Abstract][Full Text] [Related]
19. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
[TBL] [Abstract][Full Text] [Related]
20. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
